Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,340,853 shares, a growth of 91.3% from the February 15th total of 1,223,817 shares. Approximately 6.5% of the shares of the company are short sold. Based on an average daily trading volume, of 831,631 shares, the days-to-cover ratio is currently 2.8 days.
Shares of NYSEAMERICAN ATNM traded down $0.01 during trading hours on Monday, hitting $0.36. The company had a trading volume of 962,800 shares, compared to its average volume of 749,879. Actinium Pharmaceuticals has a 1-year low of $0.35 and a 1-year high of $1.61.
ATNM has been the topic of several recent analyst reports. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 27th. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 27th. Finally, Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Monday, December 25th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $3.75.
An institutional investor recently raised its position in Actinium Pharmaceuticals stock. D.A. Davidson & CO. grew its position in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 157,000 shares of the biotechnology company’s stock after buying an additional 109,000 shares during the period. D.A. Davidson & CO. owned approximately 0.20% of Actinium Pharmaceuticals worth $104,000 at the end of the most recent quarter.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.